Abstract
Previous studies demonstrated that some pyrazole derivatives could be considered as potential anticancer agents. A series of 1,3,5-triaryl-1H-pyrazole derivatives were prepared by the reaction of phenylhydrazin and different chalcones. The previous classic synthesis method was developed for a simpler procedure. The cytotoxicity of these compounds was determined against three cancer cell lines (HT-29), (MCF-7), (AGS) as well as fibroblastic cell line (NIH-3T3) using MTT assay. These biological studies proved that 5f and 5l were the most potent compounds in this series. Furthermore, 5f showed a partial selectivity in cytotoxicity effect between the cancerous and normal cell lines.
Keywords: Tri-arylpyrazole, cytotoxicity, synthesis, HT-29, MCF-7, AGS.
Letters in Drug Design & Discovery
Title:Synthesis and Anticancer Activity of 1, 3, 5-Triaryl-1H-Pyrazole
Volume: 12 Issue: 9
Author(s): Sajad Ghadbeigi, Seyed Nasser Ostad, Abbas Shafiee and Mohsen Amini
Affiliation:
Keywords: Tri-arylpyrazole, cytotoxicity, synthesis, HT-29, MCF-7, AGS.
Abstract: Previous studies demonstrated that some pyrazole derivatives could be considered as potential anticancer agents. A series of 1,3,5-triaryl-1H-pyrazole derivatives were prepared by the reaction of phenylhydrazin and different chalcones. The previous classic synthesis method was developed for a simpler procedure. The cytotoxicity of these compounds was determined against three cancer cell lines (HT-29), (MCF-7), (AGS) as well as fibroblastic cell line (NIH-3T3) using MTT assay. These biological studies proved that 5f and 5l were the most potent compounds in this series. Furthermore, 5f showed a partial selectivity in cytotoxicity effect between the cancerous and normal cell lines.
Export Options
About this article
Cite this article as:
Ghadbeigi Sajad, Nasser Ostad Seyed, Shafiee Abbas and Amini Mohsen, Synthesis and Anticancer Activity of 1, 3, 5-Triaryl-1H-Pyrazole, Letters in Drug Design & Discovery 2015; 12 (9) . https://dx.doi.org/10.2174/1570180812666150326004723
DOI https://dx.doi.org/10.2174/1570180812666150326004723 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Synthesis and Preliminarily Cytotoxicity to A549, HCT116 and MCF-7 Cell Lines of thieno[2,3-d]pyrimidine Derivatives Containing Isoxazole Moiety
Letters in Drug Design & Discovery Impact of New Technologies on Pharmacogenomics
Current Pharmacogenomics and Personalized Medicine Legumes: A Healthy and Ecological Source of Flavonoids
Current Nutrition & Food Science ErbB Antagonists Patenting: “Playing Chess with Cancer”
Recent Patents on Biotechnology Red Blood Cells as Modulators of T Cell Growth and Survival
Current Pharmaceutical Design A Rationale for Inhibiting Progesterone-Related Pathways to Combat Breast Cancer
Current Cancer Drug Targets Immunotherapeutic Options for Pediatric Malignancies
Current Immunology Reviews (Discontinued) Application of VEGF Gene Therapy in Two Basic Fields of Plastic- Reparative Surgery: Tissue Reconstruction with Flaps and Peripheral Nerve Surgery
Recent Patents on Regenerative Medicine MicroRNA Expression Profiling of Epithelial Ovarian Cancer Identifies New Markers of Tumor Subtype
MicroRNA Polyphenolic Coumpounds in Chemoprevention of Colon Cancer - Targets and Signaling Pathways
Anti-Cancer Agents in Medicinal Chemistry Clinical Considerations of Focal Drug Delivery in Cancer Treatment
Current Drug Delivery Current Advances in the Development of Anticancer Drugs Targeting Tyrosine Kinases of the Src Family
Current Drug Therapy Targeted Elimination of Leukemia Stem Cells; a New Therapeutic Approach in Hemato-Oncology
Current Drug Targets Delivery Methods of Camptothecin and Its Hydrosoluble Analogue Irinotecan for Treatment of Colorectal Cancer
Current Drug Delivery Therapeutic Drugs that Behave as Mechanism-Based Inhibitors of Cytochrome P450 3A4
Current Drug Metabolism Biomarkers in Molecularly Targeted Therapy for Cancer
Recent Patents on Biomarkers An Overview of the Design, Development and Applications of Biodegradable Stents
Drug Delivery Letters Potential Usage of ING Family Members in Cancer Diagnostics and Molecular Therapy
Current Drug Targets High Expression of miR-483-5p Predicts Chemotherapy Resistance in Epithelial Ovarian Cancer
MicroRNA Farnesyltransferase Inhibitors: A Comprehensive Review Based on Quantitative Structural Analysis
Current Medicinal Chemistry